UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

PHIA

23.52

-0.68%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

PHIA

23.52

-0.68%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

PHIA

23.52

-0.68%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

PHIA

23.52

-0.68%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

PHIA

23.52

-0.68%↓

Начало・Списък с акции・Sanofi SA

Sanofi SA

Затворен

СекторЗдравеопазване

82.48 -0.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

81.89

Максимум

83.01

Ключови измерители
By Trading Economics
Приходи	-794M 2B
Продажби	11B 24B
P/E Средно за сектора	20.323 56.063
EPS	1.53
Дивидентна доходност	5.03
Марж на печалбата	8.459
Служители	74,846
EBITDA	-3B 1.3B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+12.88% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	5.03% 2.45%
Следващи печалби	23.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.8B 99B
Предишно отваряне	82.94
Предишно затваряне	82.48

Настроения в новините

By Acuity

25%

75%

88 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

91.3 / 96.1 Подкрепа & съпротива

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2026 г., 11:40 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Spain's Santander Eyes Higher Profit After Deal Spree -- Update

12.02.2026 г., 12:40 ч. UTC

Значими двигатели на пазара

Sanofi Shares Fall After CEO Change

4.02.2026 г., 07:03 ч. UTC

Печалби

Spain's Santander Launches Buyback Alongside Earnings Beat

3.02.2026 г., 20:09 ч. UTC

Придобивния, сливания и поглъщания

Banco Santander to Buy Webster Financial in $12.3 Billion Deal -- 2nd Update

3.02.2026 г., 19:11 ч. UTC

Придобивния, сливания и поглъщания

Banco Santander to Buy Webster Financial in $12.3 Billion Deal -- Update

3.02.2026 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Banco Santander to Buy Webster Financial in $12.3 Billion Deal

2.04.2026 г., 08:43 ч. UTC

Горещи акции

Stocks to Watch Thursday: Apple, Exxon, ASML -- WSJ

30.03.2026 г., 10:40 ч. UTC

Пазарно говорене

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27.03.2026 г., 10:40 ч. UTC

Пазарно говорене

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

25.03.2026 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

11.03.2026 г., 11:02 ч. UTC

Пазарно говорене

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

27.02.2026 г., 12:50 ч. UTC

Пазарно говорене

Barclays' Exposure to Failed Lender Will Hurt Risk Sentiment -- Market Talk

25.02.2026 г., 09:22 ч. UTC

Пазарно говорене

Santander's Expectations Beyond U.K., U.S. Markets Also Attract Attention -- Market Talk

24.02.2026 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13.02.2026 г., 08:21 ч. UTC

Пазарно говорене

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12.02.2026 г., 15:20 ч. UTC

Печалби

Sanofi Shares Fall After CEO Change -- Update

10.02.2026 г., 14:07 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10.02.2026 г., 14:06 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10.02.2026 г., 14:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Completes Acquisition of Dynavax

10.02.2026 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6.02.2026 г., 12:35 ч. UTC

Печалби

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

4.02.2026 г., 16:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Santander Not Planning Any More Deals or Disposals, Chair Says -- Market Talk

4.02.2026 г., 06:55 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Santander's U.S. Deal Unlikely to Please Market -- Market Talk

4.02.2026 г., 06:49 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Santander's Webster Deal Might Disappoint Some -- Market Talk

3.02.2026 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

Banco Santander Strikes $12.3 Billion Deal for Webster Financial in U.S. Expansion -- Update

3.02.2026 г., 18:39 ч. UTC

Придобивния, сливания и поглъщания

Santander: Webster's Unique Deposit Base Enhances Combined Funding Profile, Enabling Lower Cost of Funding

3.02.2026 г., 18:38 ч. UTC

Придобивния, сливания и поглъщания

Santander Expects Combined Cost Synergies of About $800M

3.02.2026 г., 18:38 ч. UTC

Придобивния, сливания и поглъщания

Santander U.S. Combined Net Loan-To-Deposit Ratio Is Expected to Improve From 109% to About 100%.

3.02.2026 г., 18:38 ч. UTC

Придобивния, сливания и поглъщания

Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. For $12.3 Billion >WBS SAN

3.02.2026 г., 18:36 ч. UTC

Придобивния, сливания и поглъщания

Santander Expects Deal to Provide Around 7-8% Earnings Accretion

Сравнение с други в отрасъла

Ценова промяна

Sanofi SA Прогноза

Ценова цел

By TipRanks

12.88% нагоре

12-месечна прогноза

Среден 93.543 EUR 12.88%

Висок 110 EUR

Нисък 80 EUR

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Sanofi SA през последните 3 месеца.

Техническа оценка

By Trading Central

91.3 / 96.1Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

88 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.